Milestone Pharmaceuticals (MIST) Cash from Financing Activities (2018 - 2026)

Milestone Pharmaceuticals' Cash from Financing Activities history runs 9 years deep, the most recent figure standing at $94.4 million for Q1 2026.

• Quarterly Cash from Financing Activities rose 67295.71% year-over-year to $94.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $179.7 million (up 299668.33% YoY) and the FY2025 annual result came in at $85.5 million, up 166.28% from the prior year.
• Cash from Financing Activities was $94.4 million for Q1 2026 at Milestone Pharmaceuticals, up from $36.4 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $94.4 million in Q1 2026 and bottomed at -$2.8 million in Q2 2023.
• A 5-year average of $15.5 million and a median of $140000.0 in 2022 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2023 — Cash from Financing Activities tumbled 2076.43% — and 2025, when it surged 151704.17%.
• Milestone Pharmaceuticals' Cash from Financing Activities stood at $227000.0 in 2022, then tumbled by 99.56% to $1000.0 in 2023, then surged by 2300.0% to $24000.0 in 2024, then jumped by 151704.17% to $36.4 million in 2025, then jumped by 158.98% to $94.4 million in 2026.
• Business Quant data shows MIST's Cash from Financing Activities at $94.4 million in Q1 2026, $36.4 million in Q4 2025, and $48.9 million in Q3 2025.